SFI
XLRN

Susquehanna Fundamental Investments’s Acceleron Pharma XLRN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-49,172
Closed -$6.17M – 1973
2021
Q2 		$6.17M Sell
49,172
-6,078
-11% -$767K 0.11% 246
2021
Q1 		$7.49M Hold
55,250
– – 0.13% 215
2020
Q4 		$7.07M Sell
55,250
-550
-1% -$64.5K 0.13% 214
2020
Q3 		$6.28M Hold
55,800
– – 0.19% 135
2020
Q2 		$5.32M Buy
+55,800
New +$5.38M 0.25% 78

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Susquehanna Fundamental Investments's XLRN Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 49,172 shares — an estimated $6.17M sold.

Susquehanna Fundamental Investments first reported a position in XLRN in Q2 2020 and held it in 5 quarters. The position peaked at $7.49M in Q1 2021. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 49,172 Acceleron Pharma shares in Q3 2021, an estimated $6.17M.
  • Susquehanna Fundamental Investments first reported a position in Acceleron Pharma in Q2 2020 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's Acceleron Pharma position peaked at $7.49M in Q1 2021.
  • 330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.